Bobby Azamian describes how Tarsus has expanded its salesforce by 50%, and will be adding a DTC element to the launch and derive...

He describes the results of this study, which tested KERENDIA in patients with mildly reduced or preserved ejection fraction.

She describes the study results, offers her opinion on where vutrisiran may enter the treatment paradigm, and shares more about ATTR-CM...

Dr. Greenstreet shares her opinion of why she believes the data places vutrisiran in a competitive position to be a first line choice for...

He describes Skye's CB1 program and the rationale for targeting fat tissue, and why today's versions of these therapies could be better...

He discusses the sector's IPO activity YTD, what we might expect through the end of the year, and what types of companies have the best...

He describes how technology is changing healthcare at all levels, including hospitals, drug developers, the and patient experience. Plus,...

She describes what motivated her to start the Cancer Vaccine Coalition after a career as a news reporter, promising breast cancer...

He describes why this may be a good time to asset hunt, but also why Roivant has been conservative with its cash. Plus upcoming catalysts...

Katherine and Hamid describe today's event that is meant for leaders from across healthcare to discuss and think about where the industry...

He recaps this fourth Timmerman Traverse event that raised $1 million for Life Science Cares, and talks about other upcoming climbs....

Executive Director Zach Stanley describes the program and how to get involved, and recent college graduate Denise Mitchell gives us...

He describes what the funds will enable Artiva to do in the clinic, and why he believes the company's non-modified NK cell approach is...

Marcio Souza describes Praxis' small molecule and antisense oligonucleotide platforms, and previews key trials that will have near term data

Jacob Thaysen covers Illumina’s business today, including the NovaSeq X platform, multiomics, clinical and pharma industry applications,...

She describes how this PMO based antibody oligonucleotide conjugate works and why she believes the result validates her belief that...

She describes why she decided to move to the investment side and Sofinnova, what areas of science interest her today, and some thoughts...

Jay Backstrom describes the company's approach of targeting the latent form of growth factors, the importance of the upcoming SAPPHIRE...

He gives updates on programs such as IRAK4, STAT6, TYK2, and STAT3, and describes learnings in protein degradation that Kymera has...

Jay Olson shares learnings from a physician survey Oppenheimer conducted on obesity, and comments on Viking, Amgen, Madrigal, Acadia,...